KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Long-Term Debt Repayments (2017 - 2025)

Historic Long-Term Debt Repayments for Bristol Myers Squibb (BMY) over the last 14 years, with Q4 2025 value amounting to $10.1 billion.

  • Bristol Myers Squibb's Long-Term Debt Repayments changed N/A to $10.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.8 billion, marking a year-over-year increase of 34465.72%. This contributed to the annual value of $10.9 billion for FY2025, which is 28078.66% up from last year.
  • Latest data reveals that Bristol Myers Squibb reported Long-Term Debt Repayments of $10.1 billion as of Q4 2025.
  • In the past 5 years, Bristol Myers Squibb's Long-Term Debt Repayments registered a high of $10.1 billion during Q4 2025, and its lowest value of $229.0 million during Q3 2025.
  • Moreover, its 5-year median value for Long-Term Debt Repayments was $2.0 billion (2023), whereas its average is $2.7 billion.
  • As far as peak fluctuations go, Bristol Myers Squibb's Long-Term Debt Repayments surged by 45700.0% in 2022, and later crashed by 9169.27% in 2023.
  • Bristol Myers Squibb's Long-Term Debt Repayments (Quarter) stood at $500.0 million in 2021, then surged by 457.0% to $2.8 billion in 2022, then fell by 28.19% to $2.0 billion in 2023, then grew by 23.9% to $2.5 billion in 2024, then soared by 306.3% to $10.1 billion in 2025.
  • Its last three reported values are $10.1 billion in Q4 2025, $229.0 million for Q3 2025, and $2.5 billion during Q3 2024.